| FTP group (n = 26) | Placebo group (n = 22) | P-value1) | ||
---|---|---|---|---|---|
Baseline | 12Â week | Baseline | 12Â week | ||
ALT (IU/L) | Â | Â | Â | Â | Â |
Mean ± SD | 61.1 ± 25.1 | 44.9 ± 15.5 | 55.7 ± 15.1 | 53.8 ± 26.3 | 0.019* |
Median(Range) | 51.5(41–151) | 42.5(19–95) | 49(40–85) | 51(22–127) | - |
AST (IU/L) | Â | Â | Â | Â | Â |
Mean ± SD | 36.3 ± 13.8 | 27.9 ± 7.9 | 35.6 ± 8.8 | 34.8 ± 10.9 | 0.020* |
Median(Range) | 32.5(20–73) | 27(17–46) | 34(25–57) | 33.5(21–55) | - |
ALP (IU/L) | Â | Â | Â | Â | Â |
Mean ± SD | 85.0 ± 19.3 | 80.0 ± 21.9 | 71.7 ± 13.5 | 68.9 ± 13.2 | 0.471 |
Median(Range) | 81.5(52–144) | 79(46–160) | 69(48–101) | 69(43–92) | - |
gamma-GT (IU/L) | Â | Â | Â | Â | Â |
Mean ± SD | 86.3 ± 71.5 | 66.9 ± 45.6 | 104.3 ± 69.0 | 100.8 ± 68.4 | 0.254 |
Median(Range) | 64(26–360) | 52(23–195) | 95(16–231) | 91(17–253) | - |
Total bilirubin (mg/dL) | Â | Â | Â | Â | Â |
Mean ± SD | 0.98 ± 0.46 | 0.88 ± 0.38 | 0.89 ± 0.28 | 0.84 ± 0.26 | 0.664 |
Median(Range) | 0.87(0.37-2.29) | 0.79(0.4-1.98) | 0.9(0.37-1.37) | 0.81(0.37-1.34) | - |